Vor Biopharma Announces Pricing of Initial Public Offering
February 05 2021 - 6:33AM
Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering
engineered hematopoietic stem cell (eHSC) therapies combined with
targeted therapies for the treatment of cancer, today announced the
pricing of its initial public offering of 9,828,017 shares of its
common stock at a price to the public of $18.00 per share. The
gross proceeds to Vor from the offering, before deducting the
underwriting discounts and commissions and other offering expenses
payable by Vor, are expected to be approximately $176.9 million. In
addition, Vor has granted the underwriters a 30-day option to
purchase up to an additional 1,474,202 shares of its common stock
at the initial public offering price, less the underwriting
discounts and commissions. All of the shares of common stock are
being offered by Vor.
The shares are expected to begin trading on the
Nasdaq Global Market on Friday, February 5, 2021, under the ticker
symbol “VOR”. The offering is expected to close on Tuesday,
February 9, 2021, subject to customary closing conditions.
Goldman Sachs and Co. LLC, Evercore ISI, Barclays
and Stifel are acting as joint book-running managers for the
offering.
Registration statements relating to the securities
being sold in this offering have been filed with the Securities and
Exchange Commission (SEC) and have become effective. Copies of the
registration statements can be accessed through the SEC’s website
at www.sec.gov. This offering is being made only by means of a
prospectus forming part of the effective registration statements
relating to these shares. Copies of the final prospectus may be
obtained, when available, from Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New
York, New York 10282, via telephone at 1-866-471-2526, or via email
at prospectus-ny@ny.email.gs.com; Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, New York 10055, via telephone at
1-888-474-0200, or via email
at ecm.prospectus@evercore.com; Barclays Capital
Inc., Attention: Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, via telephone at
1-888-603-5847, or via email
at Barclaysprospectus@broadridge.com; or Stifel, Nicolaus
& Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, California 94104, via telephone
at 1-415-364-2720, or via email at syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell, or a solicitation of an offer to buy these securities, nor
shall there be any offer or sale of, these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Vor Biopharma Vor Biopharma
is a cell therapy company that aims to transform the lives of
cancer patients by pioneering eHSC therapies to create
next-generation, treatment-resistant transplants that unlock the
potential of targeted therapies. By removing biologically redundant
proteins from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancerous cells
while sparing healthy cells.
Investor Contact: Constantine Davides Westwicke +1
339-970-2846 constantine.davides@westwicke.com
Media Contact: Matthew Corcoran Ten Bridge
Communications +1 617-866-7350
mcorcoran@tenbridgecommunications.com
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Oct 2023 to Oct 2024